What should we do if Menactra is administered by the subcutaneous route instead of the intramuscular route?
We have received multiple inquiries about the management of people who receive Menactra by the incorrect route (subcutaneous rather than intramuscular). At this time we have no recommendation for this situation. There are no data on the response to the vaccine by the SC route. We are attempting to generate data on this issue and may have something upon which to base a recommendation in a couple of months. The manufacturer recommends revaccination. We do not recommend revaccination at this time, but are working to generate data upon which to base a recommendation.
Related Questions
- If Menactra (MCV4) is inadvertently given by the subcutaneous route rather than the intramuscular route, how should this be managed?
- Should I repeat a dose of influenza vaccine administered by an incorrect route (such as intradermal or subcutaneous)?
- What should we do if Menactra is administered by the subcutaneous route instead of the intramuscular route?
